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PPARs modulate cardiac metabolism and
mitochondrial function in diabetes
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Abstract
Diabetic cardiomyopathy is a major complication of diabetes mellitus (DM). Currently, effective treatments for
diabetic cardiomyopathy are limited. The pathophysiology of diabetic cardiomyopathy is complex, whereas
mitochondrial dysfunction plays a vital role in the genesis of diabetic cardiomyopathy. Metabolic regulation
targeting mitochondrial dysfunction is expected to be a reasonable strategy for treating diabetic cardiomyopathy.
Peroxisome proliferator-activated receptors (PPARs) are master executors in regulating glucose and lipid
homeostasis and also modulate mitochondrial function. However, synthetic PPAR agonists used for treating
hyperlipidemia and DM have shown controversial effects on cardiovascular regulation. This article reviews our
updated understanding of the beneficial and detrimental effects of PPARs on mitochondria in diabetic hearts.
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Background
Diabetes mellitus (DM) is one of the most common
chronic diseases, and its prevalence continues to in-
crease worldwide [1, 2]. Cardiovascular disease is the
leading cause of morbidity and mortality in patients with
DM. Diabetic cardiomyopathy is recognized as a distinct
disease entity, since diabetic patients have an increased
incidence of heart failure in the absence of hypertension,
coronary artery disease, or valvular heart disease [3–5].
Diabetic cardiomyopathy is characterized by cardiac lipid
accumulation, myocardial fibrosis, and increased myo-
cardial cell death, all of which lead to left ventricular re-
modeling and hypertrophy, diastolic dysfunction, and
ultimately systolic impairment [6]. The pathophysiology
of diabetic cardiomyopathy is complex and yet to be
fully elucidated. Altered cardiac metabolism and mito-
chondrial dysfunction are proposed mechanisms under-
ling diabetic cardiomyopathy [7].
Peroxisome proliferator-activated receptors (PPARs)
are nuclear hormone receptors and major executors of
modulating glucose and lipid homeostasis [8]. There are
three PPAR isoforms (PPAR-α, PPAR-β/PPAR-δ, and
PPAP-γ), which differ in distribution, function, and lig-
and specificity. Accumulating evidence suggests that
PPARs play crucial roles in cardiovascular disease [9].
PPAR isoforms are differentially expressed in the atria
and ventricles of diabetic hearts because of the increased
inflammatory cytokines and oxidative stress [10]. More-
over, we found increases in protein and messenger (m)
RNA expressions of PPAR-γ, but decreases in protein
and mRNA expressions of PPAR-α and PPAR-δ in
hypertensive hearts. Diabetic spontaneously hypertensive
rats were associated with greater reductions in cardiac
PPAR-α and PPAR-δ, but higher increases in PPAR-γ
mRNA and protein levels than were spontaneously
hypertensive rats [11]. Diabetic cardiomyopathy is asso-
ciated with an increase in cardiac PPAR-γ and a decrease
in PPAR-α, resulting in altered glucose transportation,
increased cardiac lipid accumulation, and progressive
diabetic cardiomyopathy [7, 10–12]. Calcitriol and his-
tone deacetylase inhibitor improved diabetic cardiomy-
opathy by modulating cardiac PPAR expressions and
regulating fatty acid metabolism [13, 14]. Mitochondria
are the center of fatty acid and glucose metabolism and
are thus likely to be impacted by metabolic derange-
ments in DM. Proper mitochondrial function is critical
for maintaining optimal cardiac performance. Several
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mouse models of mitochondrial defects are relevant to
human cardiomyopathy [15]. Patients with inherited
mitochondrial disorders frequently manifest cardiac dys-
function, such as dilated or hypertrophic cardiomyop-
athy and conduction defects [16]. This review elucidates
our current understanding of different PPARs and their
agonists on mitochondrial function in diabetic hearts.
Cardiac metabolism in normal and diabetic hearts
Fatty acids and glucose are principle substrates for myo-
cardial energy metabolism. Under physiological condi-
tions, fatty acid β-oxidation constitutes the major energy
source in the heart. In contrast, glycolysis predominates
during pathological stimuli, such as during ischemia and
heart failure [17, 18]. The cardiac oxygen consumption
for adenosine triphosphate (ATP) production is greater
when utilizing fatty acids than when using glucose.
However, there is increased fatty acid β-oxidation and
reduced glucose oxidation in diabetic hearts. The in-
creased fatty acid utilization in diabetic hearts is associ-
ated with reduced cardiac efficiency, which is a hallmark
of diabetic cardiomyopathy [19–21]. Diabetic hearts are
more vulnerable to ischemic injury due to their con-
strained fuel substrate flexibility. In DM, high circulating
lipid levels increase fatty acid delivery to cardiomyocytes
due to insulin resistance. Cardiac glucose uptake is
mainly controlled by insulin-mediated recruitment of
glucose transporter type four (GLUT4) from the intra-
cellular compartment to plasma membranes. High fatty
acid concentrations in diabetic hearts may impair insulin
signal transduction, thereby decreasing GLUT4 trans-
location and reducing glucose uptake [19]. In contrast,
expressions of fatty acid transporters are increased in
diabetic hearts. The enhanced cluster of differentiation
36 (CD36) and fatty acid-binding proteins can promote
fatty acid uptake, and increased fatty acids activate
PPAR-α, which facilitates cardiac fatty acid metabolism.
Activation of cardiac PPAR-α not only increases expres-
sions of genes involved in fatty acid β-oxidation but also
suppresses glucose utilization [19, 20]. Myocardial fatty
acid uptake and oxidation are increased, and glucose up-
take and oxidation are reciprocally suppressed in mice
with cardiac-specific overexpression of PPAR-α, which
exhibited cardiac dysfunction that mimics diabetic car-
diomyopathy [22]. Moreover, augmented fatty acid β-
oxidation causes accumulation of citrate in the cytosol.
High concentrations of citrate inhibit the action of phos-
phofructokinase 1 (the rate-limiting enzyme) in glycoly-
sis. Pyruvate, the product of glycolysis, is transported to
mitochondria and decarboxylated to acetyl-CoA by
pyruvate dehydrogenase. Both increased fatty acid β-
oxidation and PPAR-α activation lead to suppression of
pyruvate dehydrogenase, which impairs glucose oxida-
tion [19]. Our previous study found that diabetic hearts
expressed more fatty acid transporters and metabolic en-
zymes, including CD36, carnitine palmitoyltransferase 1
(CPT-1), and phosphorylated acetyl CoA carboxylase. In
addition, diabetic cardiomyopathy is associated with activa-
tion of enzymes controlling the formation of triglycerides,
such as diacylglycerol acyltransferase (DGAT) [13, 14]. The
shuttling of excessive fatty acids into triglyceride synthesis
serves to minimize the generation of toxic lipid metabo-
lites. However, chronic metabolic derangement results in
cardiac lipid accumulation and produces diabetic cardio-
myopathy. Alternations of cardiac metabolism in DM are
summarized in Table 1.
Mitochondrial dysfunction in diabetic hearts
Mitochondria act as the powerhouse of cells because
they generate most of the cell’s supply of ATP. Cardio-
myocytes contain a relatively large amount of mitochon-
dria (approximately 40% of the cardiomyocyte volume is
comprised of mitochondria), because the heart has a
high and continuous demand for ATP [18]. In response
to diverse physiological and nutritional conditions, it is
critical to control the metabolic activity of mitochondria
to meet cellular energy requirements.
A substantial body of evidence has demonstrated that
there is significantly impaired mitochondrial function in
diabetic cardiomyopathy. Excessive fatty acid uptake in
diabetic hearts results in an altered mitochondrial archi-
tecture and reduced expressions of genes involved in
mitochondrial oxidative phosphorylation [21]. Moreover,
PPAR-α activates genes involved in fatty acid uptake and
β-oxidation, but does not increase expressions of genes
associated with the tricarboxylic acid cycle or mitochon-
drial oxidative phosphorylation. Thus, the upregulated
mitochondrial fatty acid uptake and β-oxidation may
exceed the capacity of downstream mitochondrial respir-
ation and lead to an accumulation of toxic lipid
Table 1 Altered cardiac metabolism in diabetes
Alteration of cardiac metabolism Mechanism
Changes in fuel preference
[19–21]
Increases fatty acid β-oxidation
Decreases glucose oxidation
Defect in glucose utilization
[19, 20, 22]
Reduces GLUT4 expression and
translocation
High fatty acid oxidation suppresses
PFK1 through accumulation of
citrate in the cytosol
High fatty acid oxidation inhibits
PDH through activation of PDK
Alterations in fatty acid
utilization [13, 14, 19, 20]
Increases the expression of fatty
acid transporters
PPAR-α activation promotes the
expressions of genes that regulate
fatty acid β-oxidation
GLUT4, glucose transporter type 4; PFK1, phosphofructokinase 1; PDH, pyruvate
dehydrogenase; PDK, pyruvate dehydrogenase kinase
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metabolites, which further worsens insulin resistance. In
addition, increased fatty acid β-oxidation augments deliv-
ery of electrons to the mitochondrial electron transport
chain and results in an elevated mitochondrial inner
membrane potential, which stimulates reactive oxygen
species (ROS) generation [19, 20]. ROS directly impair
mitochondria and/or oxidize lipids to yield reactive lipid
peroxidation, as a result of inducing oxidative damage to
mitochondrial proteins that are associated with energy
metabolism and oxidative phosphorylation. Moreover,
ROS can activate mitochondrial uncoupling, and subse-
quently reduce cardiac efficiency [19–21, 23]. Excessive
fatty acids lead to the generation of ceramide. Ceramide
triggers apoptosis through nitric oxide- and peroxynitrite-
mediated opening of mitochondrial permeability transi-
tion pores and release of cytochrome c. Ceramide also
suppresses mitochondrial respiration through directly
inhibiting the activity of mitochondrial electron transport
chain complex III [19, 24]. Incomplete fat oxidation and
accumulated toxic fatty acid intermediates lead to mito-
chondrial dysfunction through hyperpolarization of the
mitochondrial inner membrane potential, mitochondrial
uncoupling, and generation of ROS [21, 23, 25].
Upregulation of mitochondrial uncoupling proteins is
another potential explanation for the reduced mitochon-
drial efficiency in diabetic hearts. Uncoupling proteins
cause proton leaks across mitochondrial membranes
from ATP synthesis, thereby decreasing the generation
of mitochondrial superoxide. Increased mitochondrial
uncoupling is presumably an adaptive mechanism; how-
ever, sustained activation of mitochondrial uncoupling
may adversely affect cardiomyocyte ATP production and
contractile function in DM [21, 25, 26]. Mitochondrial
calcium handling was proposed to represent a mechan-
ism for coordinating the ATP supply and demand for
cardiomyocyte contractions [27]. Mitochondrial calcium
uptake may also act as a spatial buffering system, which
regulates the activity of calcium-dependent processes
and signaling [28]. The mitochondrial transmembrane
potential is not only required for ATP synthesis, but also
plays a crucial role in driving calcium accumulation in
mitochondria. Disruption of the mitochondrial mem-
brane potential in the diabetic heart leads to altered
mitochondrial calcium handling which contributes to
the development of diabetic cardiomyopathy [21].
Mitochondrial DNA encodes proteins for the electron
transport chain, which is localized in the mitochondrial
inner membrane and drives ATP production through
oxidative phosphorylation. The damage to mitochondrial
DNA leads to impairment of mitochondrial respiration
and ATP synthesis. Because dysfunctional mitochondria
are a major source of ROS production, mitochondrial
DNA is a vulnerable target of ROS damage [23, 29]. Sev-
eral investigations have implied that cardiomyocyte
apoptosis promotes the development of diabetic cardio-
myopathy. Diabetic mice showed enhanced apoptotic
signaling in the heart that was associated with changes
in the mitochondrial membrane potential and the open-
ing in mitochondrial permeability transition pores [30].
Findings from mitochondrial proteomic studies in diabetic
hearts supported the role of mitochondrial-induced apop-
tosis in diabetic cardiomyopathy [31]. Furthermore, car-
diac fibrosis is a major feature of diabetic cardiomyopathy.
Apoptotic cardiomyocytes are replaced by fibrotic tissues.
Myocardial fibrosis contributes to increased stiffness and
decreased compliance of the ventricular wall, resulting in
left ventricle dysfunction. Mitochondrial dysfunction aug-
ments ROS production, which is thought to be a crucial
driving force for cardiac fibrosis [6, 32–34].
A number of studies provided evidence for mitochon-
drial alternations in hearts of patients with DM. Diastolic
dysfunction in association with a reduction in myocardial
energy metabolism was demonstrated using magnetic
resonance techniques in asymptomatic normotensive pa-
tients with well—controlled DM [35]. Mitochondria in
atrial tissues of diabetic patients revealed a sharply de-
creased capacity for respiration and increased mitochon-
drial hydrogen peroxide emissions, suggesting an increase
in oxidative stress [36]. An association of worsened car-
diac mitochondrial respiration with a reduced mitochon-
drial calcium retention capacity with decreased contractile
performance in heart tissues of diabetic patients was
shown before the onset of clinical cardiomyopathy [37].
PPARs regulate myocardial energy metabolism
in diabetes
PPAR-α was first cloned in 1990 and so named because
it was activated by the lipid-lowering drug, fibrate, which
causes hepatic peroxisome proliferation in rodents [38].
PPAR-α is the principal regulator modulating energy and
lipid homeostasis through transcriptional regulation of
fatty acid metabolic enzymes. PPAR-α is abundantly
expressed in tissues with a high capacity for mitochon-
drial fatty acid oxidation, such as the liver and heart.
Figure 1 shows that PPAR-α regulates lipid metabolism
by controlling expressions of enzymes that are directly
involved in fatty acid uptake (CD36), triglyceride synthe-
sis (DGAT), and β-oxidation (CPT-1, acyl-CoA dehydro-
genase) [12, 21, 25]. Several studies indicated that
diabetic hearts were associated with increased expression
of PPAR-α because of high levels of circulating fatty
acids [25]. However, our previous study demonstrated a
significant decline in PPAR-α and an increase in PPAR-γ
protein levels in diabetic hearts despite an increase in
cardiac fatty acid oxidation. These findings indicated
that hyperglycemia is associated with a compensatory re-
sponse for preserving the contractile function through
activation of inflammatory cytokines [39]. Mouse models
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lacking PPAR-α were protected against the development
of diabetes-induced cardiac hypertrophy. In contrast,
transgenic overexpression of PPAR-α in diabetic hearts
displayed severe cardiomyopathy and was accompanied
by myocardial triglyceride accumulation [40, 41].
PPAR-δ is expressed in multiple tissues and shares cer-
tain similarities with PPAR-α in regulating cardiac lipid
metabolism. Cardiac-specific deletion of PPAR-δ down
regulates constitutive myocardial fatty acid oxidation,
and induces myocardial lipid accumulation and cardiac
hypertrophy in mice [42]. Fatty acids and PPAR-δ-
selective ligands increase fatty acid oxidation through
transcriptional activation in both neonatal and adult car-
diomyocytes [43, 44]. However, the PPAR-δ-selective lig-
and does not modify the expression of PPAR-α in
cultured cardiomyocytes. PPAR-δ activation can partially
restore the blunted expressions of genes encoding car-
diac fatty acid oxidation enzymes in PPAR-α-knockout
mice. These findings suggest that PPAR-δ-regulated car-
diac fatty acid metabolism might not wholly interact
with PPAR-α [44, 45]. Moreover, there was increasing
myocardial glucose utilization without myocardial lipid
accumulation or cardiac dysfunction in transgenic mice
with cardiac-specific overexpression of PPAR-δ. Accord-
ingly, PPAR-α and PPAR-δ may exert distinct cardiac
metabolic regulatory actions [46].
PPAR-γ plays a crucial role in regulating lipid storage
and adipogenesis. PPAR-γ is expressed at levels far below
those of PPAR-α and PPAR-δ in the heart. PPAR-γ ligands
do not affect the fatty acid oxidation rate or metabolic
gene expression in cardiomyocytes [43]. It was suggested
that PPAR-γ modulates cardiac energy metabolism
through its effects on extra cardiac tissues. Activation of
PPAR-γ promotes glucose uptake and triglyceride synthe-
sis in adipose tissues. Reductions in circulating glucose
and fatty acid levels caused by PPAR-γ activation may
directly modulate cardiac PPAR-α and PPAR-δ activities
[45]. Cardiac-specific PPAR-γ-overexpressing transgenic
mice developed dilated cardiomyopathy with increased
myocardial lipid and glycogen stores and upregulated car-
diac expressions of genes associated with fatty acid
utilization and glucose metabolism [47]. The mechanism
underlying cardiomyopathy in PPAR-γ-overexpressing
transgenic mice was hypothesized to be combined lipid
and glucose toxicity [48].
Adenosine monophosphate-activated protein kinase
(AMPK) and PPAR-γ co-activator (PGC)-1α are two
major signaling molecules that regulate mitochondrial
biogenesis. AMPK upregulates mitochondrial biogenesis
through activation of PGC-1α, which is a master meta-
bolic regulator that coordinates gene expressions in asso-
ciation with mitochondrial biogenesis and respiratory
function [49]. Lee et al. showed that diabetic hearts have a
lower ratio of phosphorylated AMPK2α to total AMPK2α
and greater expression of PGC-1α compared to those of
control rats [13, 14]. The up regulation of PGC-1α enables
diabetic hearts to enhance their mitochondrial oxidative
capacity [25]. Therefore, up regulation of PPAR-α and
Fig. 1 Peroxisome proliferator-activated receptor (PPAR)-α regulates fatty acid utilization and β-oxidation in cardiac metabolism. Stars indicate
transporters and enzymes involved in fatty acid metabolism which are regulated by PPAR-α. FATP, fatty acid transport protein; FABP, fatty acid
binding protein; ACS, acyl-CoA synthetase; CPT-I, carnitine palmitoyltransferase-I; CPT-II, carnitine palmitoyltransferase II; TCA, tricarboxylic acid;
GLUT4, glucose transporter four; MPC, mitochondrial pyruvate carrier; and PDH, pyruvate dehydrogenase. Modified from [8]
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PGC-1α may initially be adaptive responses in diabetic
hearts [21, 25, 50]. However, sustained increases in fatty
acid β-oxidation are detrimental to cardiac mitochondria
and further promote the development of diabetic cardio-
myopathy [21, 23, 25].
PPARs modulate mitochondrial function
Effects of PPAR-α on mitochondria
Transgenic mice with cardiac-specific overexpression of
PPAR-α had disorganized mitochondria, altered mito-
chondrial cristae density and architecture, and decreased
expressions of genes involved in mitochondrial metabol-
ism, including the tricarboxylic acid cycle and oxidative
phosphorylation [51]. The cristae of mitochondria in-
creased in number and density in cardiomyocytes of
PPAR-α-null mice [52]. These findings suggest that ab-
normal expression of PPAR-α is linked to an altered
mitochondrial structure and metabolic function.
Fibrates are synthetic PPAR-α agonists that are used as
lipid-lowering agents. Several laboratory findings sug-
gested that fibrates modulate mitochondrial function
with potential beneficial or deleterious effects (Table 2).
Ureido-fibrate-5 is a potent PPAR-α agonist and exerts a
marked triglyceride-lowering effect by stimulating mito-
chondrial CPT-1-mediated fatty acid β-oxidation in both
the liver and muscles [53]. In addition, fibrates also have
an effect on glucose homeostasis. Fenofibrate improved
insulin sensitivity not only by lowering serum lipid levels
but also by enhancing mitochondrial fatty acid β-
oxidation in skeletal muscles of fructose-fed rats [54].
Two weeks of fenofibrate treatment (5 mg/kg) amelio-
rated insulin resistance accompanied by an improved
mitochondrial oxidative capacity in pediatric burn pa-
tients [55]. Mitochondrial oxidative stress was implicated
in the pathogenesis of Batten disease, a rare and fatal
autosomal recessive neurodegenerative disorder. Fenofi-
brate and gemfibrozil (1 μM) reduced mitochondrial
membrane potential depolarization, thereby inhibiting
the apoptosis of lymphoblast cells in Batten disease [56].
Pretreatment of female rats with gemfibrozil prior to
global cerebral ischemia-reperfusion resulted in neuro-
protection by modulating mitochondrial biogenesis and
apoptosis [57]. Activation of PPAR-α with WY-14,643,
an experimental ligand, or fenofibrate protects mice
from acetaminophen-induced hepatotoxicity. This pro-
tective effect is mediated by up regulating the PPAR-α
target gene that encodes mitochondrial uncoupling
protein 2, which serves to prevent mitochondria from
oxidative stress through decreasing the generation of
mitochondrial ROS [58]. However, fibrates may cause
mitochondrial dysfunction. A 24-h fenofibrate exposure
(100 μM) impaired mitochondrial function in rat skeletal
muscles through inhibiting the activity of mitochondrial
respiratory chain complex I [59]. Gemfibrozil and WY-
14,643 at toxicologically relevant concentrations altered
mitochondrial bioenergetics through inducing the mito-
chondrial permeability transition which caused inhib-
ition of oxidative phosphorylation and ATP synthesis in
mitochondria in the rat liver [60]. Chronic treatment
with WY-14,643 impaired myocardial contractile func-
tion while decreasing mitochondrial respiratory function
and increasing mitochondrial uncoupling in rats [61].
Effects of PPAR-γ on mitochondria
Overexpression of cardiac PPAR-γ via the cardiac α-
myosin heavy chain promoter produced a distorted archi-
tecture of the mitochondrial inner matrix and disrupted
cristae in PPAR-γ transgenic mice [47]. Transgenic mice
overexpressing PPAR-γ2 had significantly increased ex-
pression of mitochondrial uncoupling protein one, ele-
vated levels of PGC-1α, and reduced mitochondrial ATP
concentrations in the subcutaneous fat [62]. Cardiac ex-
pression of the gene encoding manganese superoxide dis-
mutase as a mitochondrial antioxidant was suppressed in
cardiac-specific PPAR-γ-knockout mice [63].
Thiazolidinediones (TZDs) are synthetic PPAR-γ ago-
nists and are used to treat DM. In addition to glucose
metabolism, TZDs also exert several beneficial effects in-
cluding lipid-lowering and anti-inflammation actions.
However, troglitazone and rosiglitazone were respectively
Table 2 Effects of peroxisome proliferator-activated receptor
(PPAR)-α agonists on mitochondria
PPAR-α agonists Effects on mitochondria
Potential beneficial effects





potential depolarization and apoptosis
Upregulates mitochondrial uncoupling
protein 2
Gemfibrozil [57, 56] Reduces mitochondrial membrane
potential depolarization and apoptosis
Modulates mitochondrial biogenesis
and apoptosis
WY-14,643 [58] Upregulates mitochondrial uncoupling
protein two
Ureido-fibrate-5 [53] Induces mitochondrial CPT I expression
Stimulates mitochondrial fatty acid
β-oxidation
Possible harmful effects




Induces the mitochondrial permeability
transition
CPT I, carnitine palmitoyltransferase I
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withdrawn from the market due to hepatotoxicity and in-
creased cardiovascular risk. Our previous study showed
that rosiglitazone can upregulate PPAR-γ mRNA and pro-
tein expressions, which might explain the harmful effects
of the PPAR-γ agonist in DM given that PPAR-γ is already
overexpressed in diabetic hearts [39]. In addition, we also
found that rosiglitazone significantly changed cardiac cal-
cium regulatory and electrophysiological characteristics,
thereby enhancing arrhythmogenicity in DM with hyper-
tension [64]. Numerous investigations have suggested that
TZDs have important effects on mitochondrial function
and biogenesis (Table 3). Expressions of genes in mito-
chondrial respiratory complexes I ~ IV were significantly
down regulated in subcutaneous adipose tissues of dia-
betic patients and were restored in response to rosiglita-
zone treatment. Rosiglitazone also increased the relative
amount of mitochondria in diabetic patients compared to
control groups [65]. Pioglitazone treatment significantly
increased the mitochondrial DNA copy number and
expressions of factors involved in mitochondrial biogenesis
and genes involved in the fatty acid oxidation pathway in
adipocytes of patients with DM [66]. PPAR-γ also plays a
crucial role in energy homeostasis observed in Huntington’s
disease, which is characterized by mutant Huntingtin pro-
tein aggregates in the brain. Rosiglitazone protected a
neuroblastoma cell line from a mutant Huntingtin protein-
evoked mitochondrial deficiency [67]. Rosiglitazone can
promote T lymphocyte survival by allowing cells to main-
tain the mitochondrial membrane potential following
growth factor withdrawal or glucose restriction at doses
that induce optimal PPAR-γ transcriptional activity. This
suggests that PPAR-γ activation may potentially augment
immune responses of diabetic patients [68]. However,
TZDs demonstrated varying degrees of hepatotoxicity in an
in vitro model, with troglitazone exhibiting the highest
mitochondrial toxicity, followed by rosiglitazone and then
pioglitazone. TZD-induced hepatotoxicity may involve al-
terations in mitochondrial respiratory function, changes in
membrane permeability, and mitochondrial structural
damage [69]. An in vitro study demonstrated that both
rosiglitazone and pioglitazone at supra-physiological con-
centrations (100 μM) directly inhibited mitochondrial re-
spiratory chain complex I activity and cell respiration in rat
skeletal muscles [70]. In addition, PPAR-γ activation is as-
sociated with fluid retention, heart failure, and bone loss,
thereby limiting the clinical use of TZDs.
Substantial evidence has shown that TZDs exert direct
and rapid PPAR-γ-independent effects on mitochondrial
respiration, thereby leading to changes in glycolytic me-
tabolism and fuel substrate specificity [71, 72]. It was
shown that clinically relevant concentrations of TZDs
acutely, specifically, and partially inhibit mitochondrial
pyruvate carrier activity, thereby improving cellular glu-
cose handling in human myocytes [73]. Laboratory stud-
ies revealed that TZDs have a recognition site in the
inner mitochondrial membrane that is comprised of a
protein complex, which is involved in mitochondrial
pyruvate importation [74]. Pioglitazone was shown to
specifically bind to a protein named mitoNEET, which is
an iron-containing outer mitochondrial membrane pro-
tein, that is involved in controlling maximal mitochon-
drial respiratory rates [75]. Therefore, these findings
suggest that development of novel molecules designed
to maintain this mitochondrial interaction while specific-
ally avoiding significant interactions with PPAR-γ is very
appropriate for clinical treatments.
Conclusions
Impaired mitochondrial biogenesis and function associ-
ated with derangement of cardiac metabolism play vital
roles in the pathogenesis of diabetic cardiomyopathy.
Therefore metabolic regulation targeting mitochondrial
dysfunction may show therapeutic potential for treating
diabetic cardiomyopathy. Synthetic PPAR-α and PPAR-γ
agonists not only regulate expressions of genes involving
lipid and glucose metabolism, but also modulate mito-
chondrial function and therefore appear to be promising
Table 3 Effects of peroxisome proliferator-activated receptor
(PPAR)-γ agonists on mitochondria
PPAR-γ agonists Effects on mitochondria
Potential beneficial effects
Rosiglitazone [65, 67, 68, 73, 74] Upregulates expressions of
mitochondrial respiratory complex
I ~ IV genes
Increases the relative number of
mitochondria
Maintains mitochondrial potential
to promote cell survival
Regulates mitochondrial pyruvate
import
Pioglitazone [66, 73–75] Increases the mitochondrial DNA
copy number
Increases mitochondrial biogenesis














Inhibits mitochondrial complex I
activity and cell respiration
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treatments for diabetic cardiomyopathy. However, un-
favorable effects of PPAR activation on cardiac mito-
chondria were also observed. Additional studies are
required to develop optimal pharmacological approaches
to improve mitochondrial function in diabetic hearts.
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